Gentamicin sulphate release from lost foam wollastonite scaffolds using poly(DL-lactide-co-glycolide) acid

被引:11
作者
Barrera-Mendez, F. [1 ]
Escobedo-Bocardo, J. C. [1 ]
Cortes-Hernandez, D. A. [1 ]
Almanza-Robles, J. M. [1 ]
Muzquiz-Ramos, E. M. [1 ]
机构
[1] CINVESTAV, Unidad Saltillo, Ramos Arizpe 25900, Coahuila, Mexico
关键词
Drug delivery; Gentamicin; Wollastonite scaffolds; Poly(DL-lactide-co-glycolide) acid; IN-VITRO RELEASE; SILICA SOL-GEL; MECHANICAL-PROPERTIES; INDUCED OSTEOGENESIS; BIOACTIVE CERAMICS; HYDROXYAPATITE; ANTIBIOTICS; IMPLANTS; SURFACE;
D O I
10.1016/j.ceramint.2011.03.035
中图分类号
TQ174 [陶瓷工业]; TB3 [工程材料学];
学科分类号
081705 [工业催化]; 082905 [生物质能源与材料];
摘要
A study on the gentamicin sulphate release from lost foam wollastonite scaffolds using poly(DL-lactide-co-glycolide) acid (PLGA) was performed. Scaffolds were made through the lost foam technique using two different evaporative-patterns: poly(methyl-methacrylate) (PMMA) spheres and polyurethane (PUR) sponge. With the aim to control the rate of the gentamicin sulphate delivery, poly(DL-lactide-co-glyeolide) acid was used. The porous scaffolds were gentamicin sulphate loaded by different ways. All methods showed the same gentamicin sulphate release pattern: a high rate of release in the first 24 h followed by a slow rate for a period longer than 300 h. The compression strength of the PLGA filled pores scaffolds after a degradation test was measured and compared with that of empty pores scaffolds, having as a result a notable increase in the compression strength. A hemolysis test with human blood was made to each delivery system. With only one exception, every system showed a hemolysis lower than 5%, proving to be hemocompatible. The scaffolds made by using PMMA spheres showed a better behavior in the drug release process, as well as higher mechanical properties. (C) 2011 Elsevier Ltd and Techna Group S.r.l. All rights reserved.
引用
收藏
页码:2445 / 2451
页数:7
相关论文
共 25 条
[1]
Aughenbaugh W, 2001, J BIOMED MATER RES, V57, P321, DOI 10.1002/1097-4636(20011205)57:3<321::AID-JBM1174>3.0.CO
[2]
2-S
[3]
Bai F, 2010, TISSUE ENG PT A, V16, P3791, DOI [10.1089/ten.tea.2010.0148, 10.1089/ten.TEA.2010.0148]
[4]
Osteoconduction at porous hydroxyapatite with various pore configurations [J].
Chang, BS ;
Lee, CK ;
Hong, KS ;
Youn, HJ ;
Ryu, HS ;
Chung, SS ;
Park, KW .
BIOMATERIALS, 2000, 21 (12) :1291-1298
[5]
Bioactive ceramics: the effect of surface reactivity on bone formation and bone cell function [J].
Ducheyne, P ;
Qiu, Q .
BIOMATERIALS, 1999, 20 (23-24) :2287-2303
[6]
Garcia A., 1996, REV ORTOPEDIA TRAUMA, V40, P500
[7]
Macroporous biphasic calcium phosphate ceramics: influence of macropore diameter and macroporosity percentage on bone ingrowth [J].
Gauthier, O ;
Bouler, JM ;
Aguado, E ;
Pilet, P ;
Daculsi, G .
BIOMATERIALS, 1998, 19 (1-3) :133-139
[8]
Standardization of incubation conditions for hemolysis testing of biomaterials [J].
Henkelman, Sandra ;
Rakhorst, Gerhard ;
Blanton, John ;
van Oeveren, Willem .
MATERIALS SCIENCE & ENGINEERING C-BIOMIMETIC AND SUPRAMOLECULAR SYSTEMS, 2009, 29 (05) :1650-1654
[9]
KLAWITTER JJ, 1979, THESIS CLEMSON U CLE
[10]
How useful is SBF in predicting in vivo bone bioactivity? [J].
Kokubo, T ;
Takadama, H .
BIOMATERIALS, 2006, 27 (15) :2907-2915